GeneDx Holdings (WGS) Free Cash Flow (2020 - 2026)
GeneDx Holdings has reported Free Cash Flow over the past 7 years, most recently at -$38.3 million for Q1 2026.
- Quarterly Free Cash Flow fell 579.94% to -$38.3 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$19.3 million through Mar 2026, down 208.94% year-over-year, with the annual reading at $27.0 million for FY2025, 186.81% up from the prior year.
- Free Cash Flow was -$38.3 million for Q1 2026 at GeneDx Holdings, down from $5.3 million in the prior quarter.
- Over five years, Free Cash Flow peaked at $8.0 million in Q1 2025 and troughed at -$92.1 million in Q3 2022.
- The 5-year median for Free Cash Flow is -$28.8 million (2023), against an average of -$31.9 million.
- Year-over-year, Free Cash Flow skyrocketed 258.55% in 2025 and then plummeted 579.94% in 2026.
- A 5-year view of Free Cash Flow shows it stood at -$58.2 million in 2022, then surged by 50.53% to -$28.8 million in 2023, then surged by 88.39% to -$3.3 million in 2024, then skyrocketed by 258.55% to $5.3 million in 2025, then crashed by 823.89% to -$38.3 million in 2026.
- Per Business Quant, the three most recent readings for WGS's Free Cash Flow are -$38.3 million (Q1 2026), $5.3 million (Q4 2025), and $6.8 million (Q3 2025).